<?xml version="1.0" encoding="UTF-8"?>
<p>CRS is not specific to SARS-CoV-2 infection and has been demonstrated for MERS-CoV and SARS-CoV, as well as for influenza A subtypes H5N1 and H7N9 [
 <xref rid="B71-ijms-21-05559" ref-type="bibr">71</xref>]. The hallmarks of CRS are elevated serum concentrations of pro-inflammatory cytokines including interleukin-6 (IL-6) and C-reactive protein (CRP) [
 <xref rid="B72-ijms-21-05559" ref-type="bibr">72</xref>]. A meta-analysis of nine different studies demonstrated significantly higher IL-6 levels in people with severe COVID-19 disease than with non-severe disease (mean difference: 38.6 pg/mL, 95% CI: 24.3â€“52.9 pg/mL) and was associated with excess mortality [
 <xref rid="B73-ijms-21-05559" ref-type="bibr">73</xref>].
</p>
